Go to the list of all blogs
Alicia's Avatar
published in Blogs
Mar 20, 2026
Why Is Braskem S.A. (BAK) Stock Down -11.00% Today?

Why Is Braskem S.A. (BAK) Stock Down -11.00% Today?

Key Takeaways

  • BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer

  • The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​

  • Recent trading has also reflected fading optimism around M&A and restructuring narratives that previously supported the stock at higher levels​

  • Sector peers in Latin American chemicals and materials have faced pressure from slower global growth, volatile oil prices, and currency moves, weighing on sentiment​

  • Traders are watching for any balance sheet actions, guidance updates, and macro signals that could improve visibility on Braskem’s cash flow and debt trajectory

Opening Summary

Braskem S.A. (BAK) is a leading Latin American petrochemical and plastics producer, with operations spanning basic chemicals, resins, and biopolymers. In the most recent completed U.S. trading session, American depositary shares of BAK dropped about 11%, a significant move that pushed the stock further away from recent highs and closer to the lower end of its 12‑month trading range. The selloff follows a period of mounting pressure tied to elevated leverage, a weaker credit rating, and subdued petrochemical pricing, rather than a single headline catalyst on the day. The market reaction underscores renewed skepticism around the company’s ability to navigate a tougher cycle while managing its debt load.

Macro and Sector Headwinds Weigh on Sentiment

As a commodity-linked chemicals producer, Braskem’s earnings are highly sensitive to global demand, feedstock costs, and spreads in polyethylene and polypropylene markets. Recent data show petrochemical prices and margins under strain, reflecting slower industrial activity and uneven demand in key export markets. This backdrop has pressured cash generation at BAK, constraining the pace at which the company can reduce leverage. Investor sentiment toward cyclical chemicals has turned more cautious, with many reallocating to higher-visibility sectors as macro uncertainty persists. The latest 11% drop in BAK stock fits into this broader risk-off stance toward leveraged, cyclical names.

Credit and Balance Sheet Concerns

Credit quality remains a central overhang for BAK. S&P Global Ratings previously downgraded Braskem’s rating to BB from BB+, citing sustained high leverage and a negative outlook, and also cut ratings on its senior unsecured and subordinated notes. That downgrade reinforced concerns that the company has limited room for error if margins stay compressed or capital markets tighten. While management has signaled a commitment to deleveraging, investors appear unconvinced that internal cash flows alone can materially accelerate balance sheet repair in the near term. The latest slide suggests the market is re‑pricing the equity risk premium higher to reflect that credit profile.

M&A Narratives and Volatility

Braskem’s share price over the past year has often traded more on shifting M&A and strategic speculation than on steady fundamentals. Earlier stretches of strength were fueled by hopes for a transformative transaction or strategic sale that could unlock value and de‑risk the balance sheet. Those narratives have cooled as potential deals failed to materialize on terms equity investors expected, leaving BAK exposed to the underlying cyclical and credit story. Recent commentary notes that the stock has moved closer to its recent lows, with momentum traders stepping back while only selective value-oriented buyers remain interested on large down days. The 11% decline in the latest session thus reflects both fading deal hopes and thin liquidity amplifying downside moves.​

Market Context and Trading Activity

Trading data show that BAK has been volatile, with recent sessions seeing drawdowns approaching double digits over short windows and average daily volumes in the low‑ to mid‑hundred‑thousand share range. The most recent 11% drop occurred against a mixed broader market backdrop, where major U.S. indices were modestly changed and sector peers in chemicals saw milder moves, highlighting the stock‑specific nature of the decline. Technically, BAK has been trading well below prior peaks and has struggled to hold support zones identified around recent multi-month lows, reinforcing a bearish near‑term trend. With the price now sitting closer to its 52‑week bottom than its highs, some traders view it as a potential value play, while others see a value trap without clearer catalysts.

Trending AI Robots

For traders looking to navigate volatile names like BAK, Tickeron’s curated Trending AI Robots page highlights the platform’s strongest-performing AI-driven trading bots under current market conditions. Tickeron hosts hundreds of automated strategies that collectively cover thousands of tickers, but only a select subset with standout recent performance appears in this Trending section. These bots differ by strategy type, investment horizon, risk profile, and the symbols they trade, with transparent performance metrics to help users evaluate fit. Whether focusing on momentum, mean reversion, swing trading, or multi-factor models, the Trending AI Robots page offers a data-rich starting point for investors and active traders considering how to incorporate systematic tools into their decision-making.​

What Comes Next for BAK

Looking ahead, investors in BAK will focus on the company’s next earnings release and any updated guidance on volumes, spreads, and cash flow. Key questions include whether Braskem can accelerate deleveraging, pursue asset sales, or adjust capital spending to bolster its balance sheet in a still‑soft petrochemical cycle. Analyst expectations remain cautious, with credit metrics and free cash flow generation under particular scrutiny. Sector developments such as shifts in global polyethylene demand, changes in feedstock pricing, and Brazilian macro and currency trends will also influence the outlook. Until investors see firmer evidence of improving margins or a credible path to lower leverage, BAK is likely to remain sensitive to downside macro surprises and sentiment swings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BAK

Contributor

Alicia's AvatarAlicia|Beginner

BAK's RSI Indicator climbs out of oversold territory

The RSI Indicator for BAK moved out of oversold territory on August 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 37 of the 46 cases the stock moved higher. This puts the odds of a move higher at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for BAK just turned positive on September 02, 2026. Looking at past instances where BAK's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.

Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in 183 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for BAK entered a downward trend on September 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (142.857) is very high in comparison to the industry average of (10.748). P/E Ratio (7.446) is within average values for comparable stocks, (27.909). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.769). BAK's Dividend Yield (0.311) is considerably higher than the industry average of (0.044). P/S Ratio (0.051) is also within normal values, averaging (0.578).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Dow (NYSE:DOW).

Industry description

The major diversified chemicals industry includes companies that produce a wide range of chemicals and industrial gases. The products are often used as raw materials in the manufacturing of various types of goods, including plastics, paints, carpets, and fixtures to name a few. Major companies making diversified chemicals include DuPont de Nemours Inc., Celanese Corporation, Celanese Corporation and Westlake Chemical Corporation.

Market Cap

The average market capitalization across the Chemicals: Major Diversified Industry is 2.72B. The market cap for tickers in the group ranges from 80.4K to 67.93B. SHECY holds the highest valuation in this group at 67.93B. The lowest valued company is DEVV at 80.4K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Major Diversified Industry was -2%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -21%. REX experienced the highest price growth at 3%, while BAK experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Major Diversified Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 36
Price Growth Rating: 63
SMR Rating: 84
Profit Risk Rating: 85
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
BAK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals and other related products

Industry ChemicalsMajorDiversified

Industry
Chemicals Specialty
Address
Rua Lemos Monteiro
Phone
+55 1135769531
Employees
8233
Web
https://www.braskem.com.br
Interact to see
Advertisement
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.